Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771318 | 0.89 | HTR1A (0.48) | HTR1ASLC6A4KDM4EMEN1ALDH1A1 | |
| SCHEMBL6847481 | 0.86 | HTR1A (0.78) | HTR1ASLC6A4DRD2KDM4E | |
| SCHEMBL4361658 | 0.86 | HTR1A (0.56) | HTR1ASLC6A4DRD4DRD2DRD3 | |
| SCHEMBL6903037 | 0.84 | HTR1A (0.76) | HTR1ASLC6A4DRD4DRD2DRD3 | |
| SCHEMBL6843636 | 0.81 | HTR1A (0.60) | HTR1ASLC6A4DRD2KDM4E | |
| SCHEMBL6773488 | 0.80 | ADRA2A (0.50) | HTR1ASLC6A4DRD4DRD2DRD3 | |
| SCHEMBL6844182 | 0.79 | HTR1A (0.66) | HTR1ASLC6A4DRD2 | |
| SCHEMBL6844238 | 0.79 | HTR1A (0.64) | HTR1ASLC6A4DRD2 | |
| SCHEMBL6848226 | 0.79 | HTR1A (0.64) | HTR1ASLC6A4DRD4DRD2DRD3 | |
| SCHEMBL6843626 | 0.78 | HTR1A (0.61) | HTR1ASLC6A4DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815448-B2 | FOR THERAPY OF OGNITIVE DEFICITS DUE TO AGING, STROKE, HEAD TRAUMA, ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISEASES, OR SCHIZOPHRENIA; ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA | WYETH | 2004-11-09 | — | — | US | disclosed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | HTR1A, HTR5A, HTR1D | HTR1A 1/4885SLC6A4 241/4885DRD4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.